Frederik C schreef:
[quote=junkbond]
terefenko.lib.bioinfo.pl/auid:2199524Even een vraag.Insmed heeft twee oncology compounds, rhIGFBP-3 and INSM-18. Maar bij welke hoort nordihydroguaiaretic (NDGA)?
[/quote]
(...)Towards this end, on January 5, 2007, we entered into a license agreement with NAPO Pharmaceuticals, Inc. (“NAPO”), whereby NAPO licensed from us the technology surrounding INSM-18, also known as Masoprocal. The license agreement gives NAPO the right to develop, manufacture and commercialize Masoprocal products for all indications relating specifically to diabetes, cardiac disease, vascular disease, metabolic disease and Syndrome X. The license agreement requires NAPO to make certain payments to us upon the achievement of certain milestones. Pursuant to the terms of the license agreement, on January 12, 2007, we received $500,000 from NAPO, which, as part of the license agreement, we immediately used to purchase 270,611 shares of NAPO common stock at the closing trading price of £0.94 ($1.85 in United States funds). Further, on April 16, 2007, we received $1,000,000 from NAPO for delivering certain clinical information to them in accordance with the terms of the license agreement. We recorded an unrealized loss on the NAPO stock as of June 30, 2007 in the amount of $63,460 due to the change in the closing trading price of £0.81 ($1.61 in United States funds).
Pagina 16
www.secinfo.com/d14D5a.u57Vk.htm(...)We have discovered that the combination of masoprocol known as nordihydroguaiaretic acid(..)
www.patentstorm.us/patents/5409690-de...Dus, NDGA=INSM 18
Geluk, F.